

Mario E Lacouture

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4702447/mario-e-lacouture-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

346
papers

14,771
citations

64
h-index

112
g-index

366
ext. papers

17,759
ext. citations

4.9
avg, IF

6.64
L-index

#	Paper	IF	Citations
346	Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin.. <i>Oncologist</i> , 2022 , 27, e223-e232	5.7	3
345	Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry.. <i>PLoS ONE</i> , 2022 , 17, e0262151	3.7	1
344	Dermatologic Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide.. <i>Journal of Urology</i> , 2022 , 101097JU00000000000002425	2.5	0
343	Phase 1/2 study of topical submicron particle paclitaxel for cutaneous metastases of breast cancer.. <i>Breast Cancer Research and Treatment</i> , 2022 , 1	4.4	
342	Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis.. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 174, 103696	7	0
341	Interim Results of a Pilot, Prospective, Randomized, Double-Blinded, Vehicle- and Comparator-Controlled Trial on Safety and Efficacy of a Topical Inhibitor of Janus Kinase 1/2 (Ruxolitinib INCB018424 Phosphate 1.5% Cream) for Non-Sclerotic and Superficially Sclerotic Chronic Cutaneous Graft-Versus-Host Disease. <i>Blood</i> , 2021 , 138, 3915-3915	2.2	
340	A multidisciplinary approach to optimizing care of patients treated with alpelisib.. <i>Breast</i> , 2021 , 61, 156-167	3.67	1
339	Restorative oncodermatology: Diagnosis and management of dermatologic sequelae from cancer therapies. <i>Journal of the American Academy of Dermatology</i> , 2021 , 85, 693-707	4.5	6
338	Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report. <i>Case Reports in Oncology</i> , 2021 , 14, 430-438	1	3
337	Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. <i>Oncologist</i> , 2021 , 26, 610-618	5.7	
336	Dermatologic infections in cancer patients treated with checkpoint inhibitors. <i>Journal of the American Academy of Dermatology</i> , 2021 , 85, 1528-1536	4.5	3
335	Natural history of nasal vestibulitis associated with paclitaxel, docetaxel, and other chemotherapy agents: a Minnesota Cancer Clinical Trials Network (MNCCTN) study. <i>Supportive Care in Cancer</i> , 2021 , 29, 6253-6258	3.9	0
334	Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy. <i>Cancer Discovery</i> , 2021 , 11, 2158-2167	24.4	3
333	Immune-related cutaneous adverse events due to checkpoint inhibitors. <i>Annals of Allergy, Asthma and Immunology</i> , 2021 , 126, 613-622	3.2	2
332	IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies. <i>Annals of Oncology</i> , 2021 , 32, 736-745	10.3	6
331	Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy. <i>Annals of Allergy, Asthma and Immunology</i> , 2021 , 126, 630-638	3.2	6
330	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events 2021 , 9,		58

329	Association of interleukin-6 and tumor necrosis factor- α with mortality in hospitalized patients with cancer. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 273-282	4.5	2
328	Incidence of dermatologic adverse events in patients with cancer treated with concurrent immune checkpoint inhibitors and radiation therapy: A systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 871-875	4.5	0
327	Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines. <i>Oncologist</i> , 2021 , 26, e316-e326	5.7	12
326	Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines. <i>Annals of Oncology</i> , 2021 , 32, 157-170	10.3	22
325	A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia. <i>Breast Cancer Research and Treatment</i> , 2021 , 186, 107-114	4.4	2
324	Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers. <i>Investigational New Drugs</i> , 2021 , 39, 785-795	4.3	1
323	Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1759-1764	8.9	4
322	European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force Dermatology for cancer patients Position statement.. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 ,	4.6	9
321	Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1130-1143	4.5	27
320	Dermatologic Adverse Events of Systemic Anticancer Therapies: Cytotoxic Chemotherapy, Targeted Therapy, and Immunotherapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020 , 40, 485-500	7.1	7
319	Immune checkpoint inhibitor-related dermatologic adverse events. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1255-1268	4.5	76
318	SJS/TEN 2019: From science to translation. <i>Journal of Dermatological Science</i> , 2020 , 98, 2-12	4.3	18
317	Neurokinin-1 antagonist orvepitant for EGFRi-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial. <i>BMJ Open</i> , 2020 , 10, e030114	3	4
316	Dermatologic adverse events related to the PI3K inhibitor alpelisib (BYL719) in patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020 , 183, 227-237	4.4	7
315	Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature. <i>Oncologist</i> , 2020 , 25, 140-149	5.7	22
314	Bullous disorders associated with PD-1 and PD-L1 inhibitors: Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 955-957	4.5	4
313	Alterations in and promote clinical resistance to alpelisib plus aromatase inhibitors. <i>Nature Cancer</i> , 2020 , 1, 382-393	15.4	49
312	Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. <i>Annals of Clinical and Translational Neurology</i> , 2020 , 7, 429-436	5.3	13

311	Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in Fourth-line advanced gastrointestinal stromal tumors (GIST): Analyses from INVICTUS. <i>Journal of Clinical Oncology</i> , 2020 , 38, 11539-11539	2.2	3
310	A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013. <i>Journal of Patient-Reported Outcomes</i> , 2020 , 4, 54	2.6	0
309	Dermatological Complications of Systemic Therapies for Melanoma 2020 , 1337-1358		
308	Immune checkpoint inhibitors to treat cutaneous malignancies. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1239-1253	4.5	30
307	Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 1340-1347	4.6	8
306	Vulvar lichen sclerosus in the setting of cancer treatment [A case series and review of the literature. <i>International Journal of Womens Dermatology</i> , 2020 , 6, 220	2	
305	Assessment and Treatment Outcomes of Persistent Radiation-Induced Alopecia in Patients With Cancer. <i>JAMA Dermatology</i> , 2020 , 156, 963-972	5.1	5
304	Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma. <i>Frontiers in Oncology</i> , 2020 , 10, 1045	5.3	9
303	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020 , 28, 6119-6128	3.9	6
302	The microbial flora of clinically infected cutaneous metastases: a retrospective study. <i>Clinical and Experimental Dermatology</i> , 2020 , 45, 722-726	1.8	1
301	Incidence and risk of developing photosensitivity with targeted anticancer therapies. <i>Journal of the American Academy of Dermatology</i> , 2019 , 81, 1009-1011	4.5	2
300	Randomized controlled trial of cryotherapy to prevent paclitaxel-induced peripheral neuropathy (RU221511); an ACCRU trial. <i>Breast</i> , 2019 , 48, 89-97	3.6	16
299	Markers of systemic involvement and death in hospitalized cancer patients with severe cutaneous adverse reactions. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 608-616	4.5	4
298	Treatment Outcomes of Immune-Related Cutaneous Adverse Events. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2746-2758	2.2	84
297	Cutaneous Adverse Events of Systemic Melanoma Treatments 2019 , 1-29		
296	Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy Alopecia. <i>JAMA Dermatology</i> , 2019 , 155, 724-728	5.1	26
295	Efficacy of MEK inhibition in patients with histiocytic neoplasms. <i>Nature</i> , 2019 , 567, 521-524	50.4	126
294	Hair disorders in patients with cancer. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 1179-1196	4.9	30

293	The effect of scalp cooling on CIA-related quality of life in breast cancer patients: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2019 , 175, 267-276	4.4	12
292	Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study. <i>Oncologist</i> , 2019 , 24, 414-420	5.7	26
291	Cutaneous Adverse Events of Systemic Melanoma Treatments 2019 , 743-771		
290	Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , 2019 , 20, 1070-1082	21.7	101
289	A randomized phase 2 trial of the efficacy and safety of a novel topical povidone-iodine formulation for Cancer therapy-associated Paronychia. <i>Investigational New Drugs</i> , 2019 , 37, 1247-1256	4.3	7
288	Vemurafenib acts as an aryl hydrocarbon receptor antagonist: Implications for inflammatory cutaneous adverse events. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019 , 74, 2437-2448	9.3	10
287	Drugs as a Frequent Cause of Acute Rash in Patients after CD34-Selected Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2172-2180	4.7	2
286	Nonmelanoma Skin Cancer in Childhood and Young Adult Cancer Survivors Previously Treated With Radiotherapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 237-243	7.3	4
285	Management of Immunotherapy-Related Toxicities, Version 1.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 255-289	7.3	246
284	Dermatologic Cancer Pain Syndromes 2019 , 133-138		
283	Dermatological Complications of Systemic Therapies for Melanoma 2019 , 1-22		
282	Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. <i>Nature Medicine</i> , 2019 , 25, 1839-1842	50.5	55
281	Safety of 5 α -Reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies. <i>Breast Cancer Research and Treatment</i> , 2019 , 174, 15-26	4.4	13
280	and Amplifications Determine Response to HER2 Inhibition in -Amplified Esophagogastric Cancer. <i>Cancer Discovery</i> , 2019 , 9, 199-209	24.4	79
279	Clinical Characterization of Immunotherapy-Related Pruritus Among Patients Seen in 2 Oncodermatology Clinics. <i>JAMA Dermatology</i> , 2019 , 155, 249-251	5.1	21
278	Dermatologic Adverse Events from Cancer Treatments 2019 , 131-173		2
277	Hair disorders in cancer survivors. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 1199-1213	4.5	35
276	Single-agent dabrafenib for -mutated histiocytosis. <i>Haematologica</i> , 2018 , 103, e177-e180	6.6	29

275	A Randomized Trial of Mometasone Furoate 0.1% to Reduce High-Grade Acute Radiation Dermatitis in Breast Cancer Patients Receiving Postmastectomy Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 101, 325-333	4	27
274	Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer. <i>JAMA Dermatology</i> , 2018 , 154, 670-675	39	
273	Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer. <i>Oncologist</i> , 2018 , 23, 891-899	5-7	18
272	The microbial flora of taxane therapy-associated nail disease in cancer patients. <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 607-609	4-5	5
271	First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. <i>Cancer Discovery</i> , 2018 , 8, 184-195	24-4	198
270	Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review. <i>Clinical Colorectal Cancer</i> , 2018 , 17, 85-96	3-8	38
269	Inflammatory dermatoses, infections, and drug eruptions are the most common skin conditions in hospitalized cancer patients. <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 1102-1109	4-5	15
268	SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018 , 6, 38-69	5-4	89
267	Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update. <i>American Journal of Clinical Dermatology</i> , 2018 , 19, 363-375	7-1	51
266	Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis. <i>Pediatric Blood and Cancer</i> , 2018 , 65, e26699	3	12
265	Scalp hypothermia as a preventative measure for chemotherapy-induced alopecia: a review of controlled clinical trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 720-734	4-6	23
264	Granuloma annulare associated with immune checkpoint inhibitors. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, e124-e126	4-6	16
263	Olmotinib-induced palmoplantar keratoderma. <i>British Journal of Dermatology</i> , 2018 , 178, e129-e131	4	9
262	Radiation Dermatitis: A Prevention Protocol for Patients With Breast Cancer. <i>Clinical Journal of Oncology Nursing</i> , 2018 , 22, 429-437	1-1	5
261	Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC. <i>Cancer Immunology Research</i> , 2018 , 6, 1093-1099	12-5	161
260	Pruritus Associated with Targeted Anticancer Therapies and Their Management. <i>Dermatologic Clinics</i> , 2018 , 36, 315-324	4-2	15
259	The CHANCE study: A prospective, longitudinal study of chemotherapy and hormonal therapy induced hair changes and alopecia, skin aging and nail changes in women with non-metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e12500-e12500	2-2	1
258	Treatment outcomes of cutaneous adverse events to immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e22093-e22093	2-2	1

257	Dermatologic Adverse Events 2018 , 597-620		1
256	Randomized controlled trial of cryotherapy to prevent paclitaxel-induced peripheral neuropathy (RU221511): An ACCRU trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e22075-e22075	2.2	
255	Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. <i>JAMA Oncology</i> , 2018 , 4, 384-388	13.4	191
254	A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies. <i>Supportive Care in Cancer</i> , 2018 , 26, 1169-1179	3.9	12
253	Balancing RAF, MEK, and EGFR inhibitor doses to achieve clinical responses and modulate toxicity in V600E colorectal cancer. <i>JCO Precision Oncology</i> , 2018 , 2018,	3.6	2
252	Podiatric Adverse Events and Foot Care in Cancer Patients and Survivors. <i>Journal of the American Podiatric Medical Association</i> , 2018 , 108, 508-516	1	0
251	Anticancer Therapies 2018 , 604-616		
250	Afatinib Therapy: Practical Management of Adverse Events With an Oral Agent for Non-Small Cell Lung Cancer Treatment. <i>Clinical Journal of Oncology Nursing</i> , 2018 , 22, 542-548	1.1	8
249	Management of Alopecia Due to Cancer Therapies 2018 , 621-631		1
248	Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails. <i>American Journal of Clinical Dermatology</i> , 2018 , 19, 31-39	7.1	104
247	Li-Fraumeni Syndrome-related Malignancies Involving the Genitourinary Tract: Review of a Single-institution Experience. <i>Urology</i> , 2018 , 119, 55-61	1.6	1
246	Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 317, 596-605	27.4	116
245	Oral lichenoid reactions associated with anti-PD-1/PD-L1 therapies: clinicopathological findings. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, e464-e469	4.6	46
244	Eruptive Keratoacanthomas Associated With Pembrolizumab Therapy. <i>JAMA Dermatology</i> , 2017 , 153, 694-697	5.1	49
243	A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel. <i>Investigational New Drugs</i> , 2017 , 35, 742-750	4.3	10
242	Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042). <i>Lung Cancer</i> , 2017 , 106, 76-82	5.9	6
241	Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. <i>British Journal of Dermatology</i> , 2017 , 176, 1649-1652	4	58
240	Development of Papulopustular Rosacea during Nivolumab Therapy for Metastatic Cancer. <i>Acta Dermato-Venereologica</i> , 2017 , 97, 539-540	2.2	12

239	Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group 2017 , 5, 95		999
238	Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2017 , 77, 902-910.e2	4.5	39
237	A prospective, randomized, double-blinded, split-face/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab-induced acneiform rash. <i>Journal of the American Academy of Dermatology</i> , 2017 , 77, 577-579	4.5	11
236	Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern. <i>American Journal of Surgical Pathology</i> , 2017 , 41, 1381-1389	6.7	44
235	Stoma care products represent a common and previously underreported source of peristomal contact dermatitis. <i>Contact Dermatitis</i> , 2017 , 76, 27-33	2.7	24
234	Dermatologic events from EGFR inhibitors: the issue of the missing patient voice. <i>Supportive Care in Cancer</i> , 2017 , 25, 651-660	3.9	28
233	Combination of imiquimod with cryotherapy in the treatment of penile intraepithelial neoplasia. <i>JAAD Case Reports</i> , 2017 , 3, 546-549	1.4	8
232	First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2508-2508	2.2	11
231	A phase I safety study of topical calcitriol (BPM 31543) for the prevention of chemotherapy-induced alopecia (CIA).. <i>Journal of Clinical Oncology</i> , 2017 , 35, e14064-e14064	2.2	1
230	Advanced Care Provider and Nursing Approach to Assessment and Management of Immunotherapy-Related Dermatologic Adverse Events. <i>Journal of the Advanced Practitioner in Oncology</i> , 2017 , 8, 138-145	0.7	2
229	Xerosis and pruritus as major EGFR-associated adverse events. <i>Supportive Care in Cancer</i> , 2016 , 24, 513-521	5.2	33
228	A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2016 , 27, 1712-8	10.3	38
227	A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. <i>Clinical Cancer Research</i> , 2016 , 22, 5729-5737	12.9	109
226	Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma. <i>Oncologist</i> , 2016 , 21, 1218-1229	5.7	86
225	Increased Airport Scrutiny by the Transportation Security Administration of a Patient-Passenger Carrying Ammonium Lactate-Containing Moisturizer. <i>JAMA Dermatology</i> , 2016 , 152, 1054-5	5.1	
224	Supportive Care in Patients Using Tumor Treating Fields Therapy 2016 , 103-116		1
223	Mechanisms of skin aging induced by EGFR inhibitors. <i>Supportive Care in Cancer</i> , 2016 , 24, 4241-8	3.9	17
222	Cold thermal injury from cold caps used for the prevention of chemotherapy-induced alopecia. <i>Breast Cancer Research and Treatment</i> , 2016 , 157, 395-400	4.4	17

221	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. <i>Cancer Discovery</i> , 2016 , 6, 154-654.4	269
220	A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. <i>Clinical Breast Cancer</i> , 2016 , 16, 87-94	3 1
219	Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-Basket Study. <i>Blood</i> , 2016 , 128, 480-480	2.2 3
218	Management of Dermatologic Toxicities Associated With Targeted Therapy. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016 , 7, 331-334	0.7 1
217	Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program. <i>Cancer</i> , 2016 , 122, 1228-37	6.4 8
216	Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors. <i>Oncologist</i> , 2016 , 21, 1483-1491	5.7 50
215	Dermatological adverse events with taxane chemotherapy. <i>European Journal of Dermatology</i> , 2016 , 26, 427-443	0.8 93
214	Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. <i>Cancer Immunology Research</i> , 2016 , 4, 383-9	12.5 199
213	Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. <i>European Journal of Cancer</i> , 2016 , 60, 12-25	7.5 240
212	Dermatologic Adverse Events Associated With Use of Adjuvant Lapatinib in Combination With Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer: A Case Series Analysis. <i>Clinical Breast Cancer</i> , 2016 , 16, e69-74	3 5
211	reply to the letter to the editor Possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with advanced non-small-cell lung cancer enrolled in ARCHER-1042 trial by Ceccarelli et al. <i>Annals of Oncology</i> , 2016 , 27, 2138-2139	10.3 2
210	Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis. <i>Clinical and Experimental Dermatology</i> , 2016 , 41, 8-15	1.8 27
209	A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies. <i>Supportive Care in Cancer</i> , 2015 , 23, 2231-44	3.9 22
208	Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008). <i>Cancer Immunology, Immunotherapy</i> , 2015 , 64, 437-46	7.4 79
207	Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients. <i>Cancer</i> , 2015 , 121, 60-8	6.4 18
206	Nasal vestibulitis due to targeted therapies in cancer patients. <i>Supportive Care in Cancer</i> , 2015 , 23, 2391-39	3.9 18
205	Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 75, 747-55	3.5 20
204	T-DM1-related telangiectasias: a potential role in secondary bleeding events. <i>Annals of Oncology</i> , 2015 , 26, 436-7	10.3 12

203	A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases. <i>Oncologist</i> , 2015 , 20, 789-97	5.7	48
202	Incidence and risk of xerosis with targeted anticancer therapies. <i>Journal of the American Academy of Dermatology</i> , 2015 , 72, 656-67	4.5	30
201	Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients. <i>Cancer Investigation</i> , 2015 , 33, 70-7	2.1	23
200	Reply to: "Skin moisturization for xerosis related to targeted anticancer therapies". <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, e35-6	4.5	
199	Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. <i>Annals of Oncology</i> , 2015 , 26, 2375-91	10.3	828
198	Alopecia in patients treated with molecularly targeted anticancer therapies. <i>Annals of Oncology</i> , 2015 , 26, 2496-502	10.3	30
197	Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. <i>Annals of Oncology</i> , 2015 , 26, 2017-26	10.3	72
196	Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 2015 , 373, 1733-47	59.2	215
195	Clinical and dermoscopic features of combined cutaneous squamous cell carcinoma (SCC)/neuroendocrine [Merkel cell] carcinoma (MCC). <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, 968-75	4.5	16
194	Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. <i>Cancer Discovery</i> , 2015 , 5, 64-71	24.4	101
193	Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trials. <i>Acta Oncologica</i> , 2015 , 54, 124-32	3.2	9
192	Management of dermatologic toxicities. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 686-9	7.3	10
191	Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center. <i>British Journal of Haematology</i> , 2015 , 171, 84-90	4.5	11
190	Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis. <i>Pediatric Blood and Cancer</i> , 2015 , 62, 798-806	3	22
189	The risk of nail changes with taxane chemotherapy: a systematic review of the literature and meta-analysis. <i>British Journal of Dermatology</i> , 2015 , 173, 842-5	4	28
188	Histopathologic Features of Cutaneous Acute Graft-Versus-Host Disease in T-Cell-Depleted Peripheral Blood Stem Cell Transplant Recipients. <i>American Journal of Dermatopathology</i> , 2015 , 37, 523-9	6.9	10
187	Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. <i>Clinical Cancer Research</i> , 2015 , 21, 1313-20	12.9	189
186	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. <i>Blood</i> , 2015 , 126, 481-481	2.2	

185	Efficacy of skin-directed therapy for cutaneous metastases from advanced cancer: a meta-analysis. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3144-55	2.2	105
184	Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy. <i>Journal of Clinical Oncology</i> , 2014 , 32, e54-6	2.2	24
183	Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series. <i>Breast Cancer Research and Treatment</i> , 2014 , 146, 451-6	4.4	23
182	EMPACT syndrome: limited evidence despite a high-risk cohort. <i>Journal of Neuro-Oncology</i> , 2014 , 119, 129-34	4.8	3
181	Current practices in the management of adverse events associated with targeted therapies for advanced renal cell carcinoma: a national survey of oncologists. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 341-7	3.3	19
180	Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma. <i>Seminars in Oncology</i> , 2014 , 41 Suppl 4, S1-14	5.5	55
179	Ipilimumab in patients with cancer and the management of dermatologic adverse events. <i>Journal of the American Academy of Dermatology</i> , 2014 , 71, 161-9	4.5	142
178	Overview and management of dermatologic events associated with targeted therapies for medullary thyroid cancer. <i>Thyroid</i> , 2014 , 24, 1329-40	6.2	28
177	Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine. <i>Breast Cancer Research and Treatment</i> , 2014 , 147, 631-8	4.4	21
176	Dermoscopic findings in cutaneous metastases. <i>JAMA Dermatology</i> , 2014 , 150, 429-33	5.1	40
175	Rash to the mTOR inhibitor everolimus: systematic review and meta-analysis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014 , 37, 266-71	2.7	18
174	Life-threatening dermatologic adverse events in oncology. <i>Anti-Cancer Drugs</i> , 2014 , 25, 225-34	2.4	45
173	Dermatologic infections in cancer patients. <i>Cancer Treatment and Research</i> , 2014 , 161, 299-317	3.5	9
172	Overview photography and short-term mole monitoring in patients taking a BRAF inhibitor. <i>JAMA Dermatology</i> , 2014 , 150, 1010-1	5.1	2
171	Differential radiation dermatitis in native skin and an autologous transplanted myocutaneous flap. <i>JAMA Dermatology</i> , 2014 , 150, 1365-7	5.1	0
170	Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014 , 61, 309-17	13.4	71
169	Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. <i>BMC Cancer</i> , 2014 , 14, 5	4.8	3
168	Clinical and histologic characterization of dermatologic adverse events from the pan-PI3K inhibitor buparlisib (BKM-120).. <i>Journal of Clinical Oncology</i> , 2014 , 32, e20639-e20639	2.2	4

167	Vemurafenib Has Potent Antitumor Activity in Patients with Relapsed/Refractory BRAF Mutant Hairy Cell Leukemia. <i>Blood</i> , 2014 , 124, 24-24	2.2	
166	Unraveling the Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms through Whole Exome Sequencing. <i>Blood</i> , 2014 , 124, 1887-1887	2.2	
165	Dermatological adverse events from BRAF inhibitors: a growing problem. <i>Current Oncology Reports</i> , 2013 , 15, 249-59	6.3	41
164	Experiences with the FACT-EGFRI-18 instrument in EGFRI-associated mucocutaneous adverse events. <i>Supportive Care in Cancer</i> , 2013 , 21, 1919-26	3.9	15
163	The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18). <i>Supportive Care in Cancer</i> , 2013 , 21, 1033-41	3.9	31
162	Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review. <i>Supportive Care in Cancer</i> , 2013 , 21, 1167-74	3.9	53
161	Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. <i>Investigational New Drugs</i> , 2013 , 31, 1078-86	4.3	76
160	Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. <i>American Journal of Clinical Dermatology</i> , 2013 , 14, 327-33	7.1	105
159	The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2013 , 69, e121-8	4.5	100
158	Skinflammation and drug toxicity--a delicate balance. <i>Science Translational Medicine</i> , 2013 , 5, 199fs33	17.5	7
157	The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. <i>Investigational New Drugs</i> , 2013 , 31, 787-97	4.3	49
156	Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2013 , 69, 708-720	4.5	71
155	Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. <i>Supportive Care in Cancer</i> , 2013 , 21, 2933-48	3.9	146
154	Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013 , 13, 424-9	2	23
153	Dermatitis and Alopecia 2013 , 147-166		
152	Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization. <i>European Journal of Haematology</i> , 2013 , 90, 142-50	3.8	26
151	Skin necrosis induced by generic enoxaparin. <i>American Journal of Hematology</i> , 2013 , 88, 339	7.1	4
150	Translation and linguistic validation of the FACT-EGFRI-18 quality of life instrument from English into Dutch. <i>European Journal of Oncology Nursing</i> , 2013 , 17, 802-7	2.8	4

149	Dermatologic adverse events to targeted therapies in lower GI cancers: clinical presentation and management. <i>Current Treatment Options in Oncology</i> , 2013 , 14, 389-404	5.4	14
148	Tracking of second primary melanomas in vemurafenib-treated patients. <i>JAMA Dermatology</i> , 2013 , 149, 488-90	5.1	23
147	Dermatologic adverse events associated with afatinib: an oral ErbB family blocker. <i>Expert Review of Anticancer Therapy</i> , 2013 , 13, 721-8	3.5	63
146	Bio-radiation dermatitis: the need of a new grading: in regard to Bernier et al: <i>Ann Oncol</i> 2011; 22(10): 2191-2200. <i>Annals of Oncology</i> , 2013 , 24, 2463-5	10.3	13
145	In reply. <i>Oncologist</i> , 2013 , 18, e18	5.7	2
144	Alopecia with endocrine therapies in patients with cancer. <i>Oncologist</i> , 2013 , 18, 1126-34	5.7	35
143	Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. <i>Clinical Cancer Research</i> , 2013 , 19, 2257-64	12.9	108
142	Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4. <i>Dermatologic Therapy</i> , 2013 , 26, 135-48	2.2	37
141	Small Molecule Multikinase Inhibitors 2013 , 196-207		
140	Alkylating Agents 2013 , 145-159		
139	Analysis of dermatologic events in vemurafenib-treated patients with melanoma. <i>Oncologist</i> , 2013 , 18, 314-22	5.7	162
138	Topoisomerase-Interacting Agents 2013 , 170-183		
137	Skin toxicity of targeted cancer agents: mechanisms and intervention. <i>Future Oncology</i> , 2013 , 9, 1161-70, 6		23
136	Radiation-Induced Skin Reactions 2013 , 264-280		
135	Antimicrotubule Agents 2013 , 208-214		1
134	Types of Dermatologic Reactions 2013 , 33-46		
133	Paraneoplastic, Inherited Cancer Syndrome, and Environmental Carcinogen-Related Dermatoses 2013 , 75-85		
132	Topical Anticancer Therapies 2013 , 301-309		

131 Extravasation Reactions **2013**, 295-300

130 Structure and Function of the Integumentary System and the Dermatology Lexicon **2013**, 24-32

129 Phase II Trial Of The BRAF Inhibitor, Vemurafenib, In Patients With BRAF Mutant Relapsed Or Refractory Hairy Cell Leukemia. *Blood*, **2013**, 122, 2876-2876 2.2 1

128 Increased Incidence Of Melanoma and Non-Melanoma Skin Cancers In Patients With Hairy Cell Leukemia: A Single Institution Experience With 267 Patients From Memorial Sloan-Kettering Cancer Center. *Blood*, **2013**, 122, 5274-5274 2.2

127 Systemic anticancer agents **2013**, 397-407.e2 1

126 Diagnosis of blue nevus-like metastatic uveal melanoma confirmed by fluorescence in situ hybridization (FISH) for monosomy 3. *Journal of Cutaneous Pathology*, **2012**, 39, 621-5 1.7 9

125 Disseminated Mycobacterium marinum infection in a hematopoietic stem cell transplant recipient. *Transplant Infectious Disease*, **2012**, 14, 410-4 2.7 9

124 Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern?. *Journal of Clinical Oncology*, **2012**, 30, 329-30 2.2 50

123 The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis. *European Journal of Cancer*, **2012**, 48, 340-6 7.5 40

122 The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis. *Journal of the American Academy of Dermatology*, **2012**, 67, 400-8 4.5 50

121 Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. *Journal of the American Academy of Dermatology*, **2012**, 67, 1025-39 4.5 188

120 Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis. *Breast Cancer Research and Treatment*, **2012**, 135, 347-54 4.4 24

119 Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors. *Cancer*, **2012**, 118, 5078-83 6.4 26

118 The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. *Investigational New Drugs*, **2012**, 30, 1773-81 4.3 44

117 Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib. *Breast Cancer Research and Treatment*, **2012**, 132, 833-42 4.4 25

116 Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib. *Annals of Oncology*, **2012**, 23, 2103-2108 10.3 32

115 Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 1125-33 5.6 41

114 Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. *Oncologist*, **2012**, 17, 135-44 5.7 74

113	Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2375-83	2.2	175
112	Characteristics of oral mucosal events related to bevacizumab treatment. <i>Oncologist</i> , 2012 , 17, 274-8	5.7	20
111	Scarring, disfigurement, and quality of life in long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor study. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2466-74	2.2	82
110	The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life. <i>Journal of Drugs in Dermatology</i> , 2012 , 11, e61-5	2.2	38
109	The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. <i>Clinical Colorectal Cancer</i> , 2011 , 10, 333-9	3.8	30
108	Cyclophosphamide-associated acneiform drug eruption in a patient with multiple myeloma. <i>Journal of the American Academy of Dermatology</i> , 2011 , 65, 657-659	4.5	5
107	The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies. <i>Journal of the American Academy of Dermatology</i> , 2011 , 65, 624-635	4.5	61
106	Management of treatment-related dermatologic adverse effects 2011 , 115-120		
105	Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors. <i>Current Opinion in Oncology</i> , 2011 , 23, 343-51	4.2	23
104	Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. <i>International Journal of Dermatology</i> , 2011 , 50, 129-46	1.7	45
103	Higher severity grade of erlotinib-induced rash is associated with lower skin phototype. <i>Clinical and Experimental Dermatology</i> , 2011 , 36, 733-8	1.8	12
102	Cutaneous and mucosal reactions to oncologic therapy. <i>Dermatologic Therapy</i> , 2011 , 24, 385	2.2	2
101	Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. <i>Dermatologic Therapy</i> , 2011 , 24, 386-95	2.2	72
100	Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). <i>Investigational New Drugs</i> , 2011 , 29, 1114-21	4.3	64
99	Skin care management in cancer patients: an evaluation of quality of life and tolerability. <i>Supportive Care in Cancer</i> , 2011 , 19, 545-54	3.9	26
98	Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. <i>Supportive Care in Cancer</i> , 2011 , 19, 1079-95	3.9	306
97	Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer. <i>Oncologist</i> , 2011 , 16, 1508-19	5.7	47
96	Case series of dermatologic events associated with the insulin-like growth factor receptor 1 inhibitor cixutumumab. <i>Journal of Clinical Oncology</i> , 2011 , 29, e638-40	2.2	5

95	Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. <i>Clinical Cancer Research</i> , 2011 , 17, 2997-3004	12.9	119
94	Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents. <i>Archives of Dermatology</i> , 2011 , 147, 1403-9		37
93	The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysis. <i>Annals of Oncology</i> , 2011 , 22, 2366-2374	10.3	17
92	Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 8520-8520	2.2	12
91	Dermatologic Manifestations of Systemic Oncologic Therapy of Cutaneous Malignancies 2011 , 379-385		
90	Risk of Skin Rash in Proteasome Inhibitor Bortezomib: A Systematic Literature Review and Meta-Analysis. <i>Blood</i> , 2011 , 118, 5120-5120	2.2	
89	A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension. <i>Clinical Pharmacology and Therapeutics</i> , 2010 , 87, 303-10	6.1	72
88	Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients. <i>Clinical Cancer Research</i> , 2010 , 16, 4452-60	12.9	40
87	Reply to M. Rother. <i>Journal of Clinical Oncology</i> , 2010 , 28, e475-e476	2.2	
86	Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1351-7	2.2	347
85	Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 47-53	9.7	127
84	Epidermal growth factor receptor inhibition with erlotinib for palmoplantar keratoderma. <i>Journal of the American Academy of Dermatology</i> , 2010 , 63, e58-9	4.5	12
83	Acneiform rash as a reaction to radiotherapy in a breast cancer patient. <i>The Journal of Supportive Oncology</i> , 2010 , 8, 268-71		10
82	Photodermatosis associated with eculizumab (Soliris): a novel monoclonal antibody directed against the complement protein C5. <i>American Journal of Hematology</i> , 2010 , 85, 392-3	7.1	4
81	Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors. <i>Community Oncology</i> , 2010 , 7, 23-29		21
80	Treatment of multiple keratoacanthomas with erlotinib. <i>International Journal of Clinical Oncology</i> , 2010 , 15, 413-5	4.2	6
79	A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. <i>Supportive Care in Cancer</i> , 2010 , 18, 509-22	3.9	129
78	Unanticipated toxicities from anticancer therapies: survivors' perspectives. <i>Supportive Care in Cancer</i> , 2010 , 18, 1461-8	3.9	54

77	Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. <i>Cancer</i> , 2010 , 116, 3916-23	6.4	122
76	PLX4032 (RG7204), a selective mutant RAF inhibitor: Clinical and histologic characteristics of therapy-associated cutaneous neoplasms in a phase I trial.. <i>Journal of Clinical Oncology</i> , 2010 , 28, 8592-8592	2.2	8
75	Dermatologic Toxicities 2010 , 361-380		1
74	Dermatologic toxicities of targeted anticancer therapies. <i>The Journal of Supportive Oncology</i> , 2010 , 8, 149-61		37
73	Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis. <i>Oncology</i> , 2009 , 77, 124-33	3.6	52
72	Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). <i>Oncologist</i> , 2009 , 14, 291-302	5.7	84
71	Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2009 , 7, 11-9	3.3	72
70	Eosinophilic rash secondary to temsirolimus. <i>Clinical Genitourinary Cancer</i> , 2009 , 7, E34-6	3.3	14
69	Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. <i>Cancer</i> , 2009 , 115, 1286-99	6.4	65
68	Analysis of dermatologic events in patients with cancer treated with lapatinib. <i>Breast Cancer Research and Treatment</i> , 2009 , 114, 485-93	4.4	70
67	Blackberry-induced hand-foot skin reaction to sunitinib. <i>Investigational New Drugs</i> , 2009 , 27, 389-90	4.3	24
66	Dermatologic issues in adult survivors of childhood cancer. <i>Journal of Cancer Survivorship</i> , 2009 , 3, 158-63.	3.1	9
65	Effect of sunitinib on renal cell carcinoma cutaneous metastasis. <i>International Journal of Dermatology</i> , 2009 , 48, 1269-70	1.7	3
64	Magnetic resonance imaging of paronychia induced by cetuximab. <i>Clinical and Experimental Dermatology</i> , 2009 , 34, e258-9	1.8	2
63	NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009 , 7 Suppl 1, S5-21; quiz S22-4	7.3	87
62	Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. <i>Current Oncology</i> , 2009 , 16, 16-26	2.8	101
61	Final STEPP results of prophylactic versus reactive skin toxicity (ST) treatment (tx) for panitumumab (pmab)-related ST in patients (pts) with metastatic colorectal cancer (mCRC). <i>Journal of Clinical Oncology</i> , 2009 , 27, CRA4027-CRA4027	2.2	6
60	The growing importance of skin toxicity in EGFR inhibitor therapy. <i>Oncology</i> , 2009 , 23, 194, 196	1.8	6

59	Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis. <i>The Journal of Supportive Oncology</i> , 2009 , 7, 211-7		19
58	HSHV/HHV8-Associated Primary Cutaneous Plasmablastic Lymphoma in a Patient with Castleman Disease and Kaposi Sarcoma. <i>Journal of Cutaneous Pathology</i> , 2008 , 33, 67-67	1.7	
57	Completeness in the reporting of dermatologic adverse drug reactions associated with monoclonal antibody epidermal growth factor receptor inhibitors in phase II and III colorectal cancer clinical trials. <i>Clinical Colorectal Cancer</i> , 2008 , 7, 309-14	3.8	13
56	Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. <i>European Journal of Cancer</i> , 2008 , 44, 781-90	7.5	108
55	Cutaneous toxicities of targeted cancer therapies. <i>Community Oncology</i> , 2008 , 5, 413-414		3
54	Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. <i>Acta Oncologica</i> , 2008 , 47, 176-86	3.2	169
53	Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. <i>Oncologist</i> , 2008 , 13, 1001-11	5.7	273
52	An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors. <i>Clinical Journal of Oncology Nursing</i> , 2008 , 12, 283-90	1.1	48
51	Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. <i>Annals of Oncology</i> , 2008 , 19, 1955-61	10.3	175
50	The role of inhibitors of the epidermal growth factor in management of head and neck cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008 , 6, 696-706	7.3	11
49	Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. <i>Supportive Care in Cancer</i> , 2008 , 16, 557-66	3.9	94
48	Hand foot skin reaction (HFSR) by the multikinase inhibitors (MKIs) sorafenib and sunitinib: Impact on quality of life (QoL). <i>Journal of Clinical Oncology</i> , 2008 , 26, 16122-16122	2.2	15
47	Economic impact associated with the management of dermatologic adverse drug reactions (dADRs) induced by EGFR inhibitors (EGFRIs) in lung cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 19094-19094	2.2	3
46	Correlation of patient characteristics and NCI-Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 grading with dermatology-related quality of life (QoL) in patients with EGFR inhibitor-induced rash. <i>Journal of Clinical Oncology</i> , 2008 , 26, 9559-9559	2.2	7
45	Gadolinium-associated nephrogenic systemic fibrosis. <i>Community Oncology</i> , 2008 , 5, 325-326		1
44	Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. <i>Oncologist</i> , 2007 , 12, 610-21	5.7	277
43	Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2007 , 23, 42-5	2.4	40
42	Neutrophilic dermatitis associated with bortezomib in a patient with multiple myeloma. <i>Annals of Oncology</i> , 2007 , 18, 1744-5	10.3	3

41	Hand-foot and stump syndrome to sorafenib. <i>Journal of Clinical Oncology</i> , 2007 , 25, 341-3	2.2	43
40	Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. <i>Oncology</i> , 2007 , 72, 152-9	3.6	141
39	The era of targeted therapies: increasing role for novel oncologic drugs in dermatology. <i>Archives of Dermatology</i> , 2007 , 143, 788-9		2
38	Temporal dependence of the effect of radiation on erlotinib-induced skin rash. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2140; author reply 2141	2.2	22
37	Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer. <i>Cancer Nursing</i> , 2007 , 30, S17-26	2.6	21
36	p63 in Primary Cutaneous Carcinosarcoma. <i>American Journal of Dermatopathology</i> , 2007 , 29, 374-7	0.9	21
35	Development of a functional assessment of side-effects to therapy (FAST) questionnaire to assess dermatology-related quality of life in patients treated with EGFR inhibitors (EGFRI): The FAST-EGFRI. <i>Journal of Clinical Oncology</i> , 2007 , 25, 19532-19532	2.2	3
34	Influence of skin color in the development of erlotinib-induced rash: A report from the SERIES clinic. <i>Journal of Clinical Oncology</i> , 2007 , 25, 9127-9127	2.2	7
33	Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective. <i>Skin Therapy Letter</i> , 2007 , 12, 1-5	1.8	20
32	Dermatologic challenges in cancer patients and survivors. <i>Oncology</i> , 2007 , 21, 1462-72; discussion 1473, 1476, 1481 passim	1.8	13
31	Clinical presentation and pathophysiology of EGFRI dermatologic toxicities. <i>Oncology</i> , 2007 , 21, 4-9	1.8	31
30	Clinical management of EGFRI dermatologic toxicities: US perspective. <i>Oncology</i> , 2007 , 21, 17-21	1.8	6
29	Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. <i>Oncology</i> , 2007 , 21, 34-6	1.8	72
28	Non-rash skin toxicities associated with novel targeted therapies. <i>Clinical Lung Cancer</i> , 2006 , 8 Suppl 1, S36-42	4.9	21
27	Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia. <i>Journal of Molecular Diagnostics</i> , 2006 , 8, 604-12	5.1	29
26	Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. <i>British Journal of Dermatology</i> , 2006 , 154, 191-2	4	42
25	The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome. <i>British Journal of Dermatology</i> , 2006 , 155, 852-4	4	70
24	Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. <i>Clinical and Experimental Dermatology</i> , 2006 , 31, 783-5	1.8	55

23	Mechanisms of cutaneous toxicities to EGFR inhibitors. <i>Nature Reviews Cancer</i> , 2006 , 6, 803-12	31.3	555
22	The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors. <i>The Journal of Supportive Oncology</i> , 2006 , 4, 236-8		52
21	The promise of molecular targeted therapies: protein kinase inhibitors in the treatment of cutaneous malignancies. <i>Journal of the American Academy of Dermatology</i> , 2005 , 53, 291-302	4.5	38
20	Human papillomavirus-associated dysplastic condyloma of the tongue treated with Mohs micrographic surgery. <i>Dermatologic Surgery</i> , 2005 , 31, 477-9	1.7	1
19	Ossified soft tissue leiomyoma in a patient with sickle cell anemia. <i>Journal of Cutaneous Pathology</i> , 2005 , 32, 696-9	1.7	7
18	Skin rash in a transplant patient receiving multiple drugs. <i>Cleveland Clinic Journal of Medicine</i> , 2003 , 70, 1071-5	2.8	1
17	A comparison of type I collagen, fibronectin, and vitronectin in supporting adhesion of mechanically strained osteoblasts. <i>Journal of Bone and Mineral Research</i> , 2002 , 17, 481-92	6.3	36
16	gp49B1-alpha(v)beta3 interaction inhibits antigen-induced mast cell activation. <i>Nature Immunology</i> , 2001 , 2, 436-42	19.1	71
15	Hair Disorders Associated with Anticancer Agents100-114		
14	Nail Abnormalities in Oncology Practice115-121		1
13	Management Options for Hot Flashes in Cancer Patients131-143		
12	Antimetabolite Reactions160-169		
11	Agents for the Management of Hematologic Reactions257-263		
10	Appearance-Related Concerns in the Cancer Patient410-415		
9	Histone Deacetylase Inhibitors, Proteasome Inhibitors, Demethylating Agents, Arsenicals, and Retinoids215-223		
8	Hematopoietic Stem Cell Transplantation and Graft Versus Host Disease281-294		
7	Dermatologic Techniques and Procedures401-409		
6	Oral Mucosal Complications of Cancer Therapy87-99		1

5	Dermatologic Therapeutics and Formulations	384-400	
4	Late Dermatologic Conditions	337-364	
3	Life-threatening (Serious) Dermatologic Adverse Events	310-318	
2	Psychosocial Issues in Oncology: Clinical Management of Psychosocial Distress, Health-Related Quality of Life, and Special Considerations in Dermatologic Oncology	60-68	1
1	Grading Dermatologic Adverse Events in Clinical Trials Using CTCAE v4.0	47-59	1